Analysts Set Intuitive Surgical, Inc. (NASDAQ:ISRG) Target Price at $613.10

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) have been given a consensus rating of “Moderate Buy” by the twenty-one analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and sixteen have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $613.10.

Several research firms recently commented on ISRG. Raymond James upped their price target on shares of Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research report on Friday, January 24th. Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 19th. Bernstein Bank boosted their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. JPMorgan Chase & Co. upped their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $670.00 price target (up from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th.

Intuitive Surgical Trading Down 2.4 %

Shares of NASDAQ:ISRG opened at $591.79 on Friday. The firm has a 50 day simple moving average of $565.45 and a 200-day simple moving average of $525.60. Intuitive Surgical has a twelve month low of $364.17 and a twelve month high of $616.00. The company has a market capitalization of $210.78 billion, a PE ratio of 92.32, a P/E/G ratio of 5.85 and a beta of 1.39.

Insider Transactions at Intuitive Surgical

In related news, CFO Jamie Samath sold 108 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total transaction of $58,542.48. Following the completion of the sale, the chief financial officer now owns 8,757 shares of the company’s stock, valued at approximately $4,746,819.42. This represents a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 376 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,967,734. This trade represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,348 shares of company stock worth $3,587,582 in the last three months. Company insiders own 0.90% of the company’s stock.

Institutional Trading of Intuitive Surgical

Several large investors have recently bought and sold shares of the company. Atala Financial Inc acquired a new stake in shares of Intuitive Surgical during the fourth quarter worth approximately $25,000. Berbice Capital Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at $26,000. Parvin Asset Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at $26,000. BankPlus Trust Department acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at $28,000. Finally, Hurley Capital LLC acquired a new position in Intuitive Surgical during the fourth quarter worth about $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.